Brian H. Fasig

Brian H. Fasig

Auto-generated profile, based on publicly available information

Brian H. Fasig

Surgical Outcomes and Analysis Department, Kaiser Permanente, San Diego, California

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2023 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
KOKanu Okike
Kanu Okike
HPHeather Prentice
Heather Prentice
PCPriscilla H. Chan
Priscilla H. Chan
BFBrian H. Fasig
Brian H. Fasig
EPElizabeth W (Liz) Paxton
Elizabeth W (Liz) Paxton
FCFoster Chen
Foster Chen
Background: Practice patterns regarding the use of unipolar hemiarthroplasty, bipolar hemiarthroplasty, and total hip arthroplasty (THA) for femoral neck fractures in older patients vary widely. This is due in part to limited data stipulating the specific circumstances under which each form of arthroplasty provides the most predictable outcome. The purpose of this study was to investigate the patient characteristics for which unipolar hemiarthroplasty, bipolar hemiarthroplasty, or THA might be preferable due to a lower risk of all-cause revision. Methods: A U.S. health-care system’s hip fracture registry was used to identify patients ≥60 years old who underwent unipolar hemiarthroplasty, bipolar hemiarthroplasty, or THA for hip fracture from 2009 through 2021. Unipolar and bipolar hemiarthroplasty were compared with THA within patient subgroups defined by age (60 to 79 versus ≥80 years) and American Society of Anesthesiologists (ASA) classification (I or II versus III); patients with an ASA classification of IV or higher were excluded. Multivariable Cox proportional hazard regression analysis was used to evaluate all-cause revision risk while adjusting for confounders, with mortality considered as a competing risk. Results: There were 14,277 patients in the final sample (median age, 82 years; 70% female; 80% White; 69% with an ASA classification of III; median follow-up, 2.7 years), and the procedures included 7,587 unipolar hemiarthroplasties, 5,479 bipolar hemiarthroplasties, and 1,211 THAs. In the multivariable analysis of all patients, both unipolar (hazard ratio [HR] = 2.15, 95% confidence interval [CI] = 1.48 to 3.12; p < 0.001) and bipolar (HR = 1.92, 95% CI = 1.31 to 2.80; p < 0.001) hemiarthroplasty had higher revision risks than THA. In the age-stratified multivariable analysis of patients aged 60 to 79 years, both unipolar (HR = 2.17, 95% CI = 1.42 to 3.34; p = 0.004) and bipolar (HR = 1.69, 95% CI = 1.08 to 2.65; p = 0.022) hemiarthroplasty also had higher revision risks than THA. In the ASA-stratified multivariable analysis, patients with an ASA classification of I or II had a higher revision risk after either unipolar (HR = 3.52, 95% CI = 1.87 to 6.64; p < 0.001) or bipolar (HR = 2.31, 95% CI = 1.19 to 4.49; p = 0.013) hemiarthroplasty than after THA. No difference in revision risk between either of the hemiarthroplasties and THA was observed among patients with an age of ≥80 years or those with an ASA classification of III. Conclusions: In this study of hip fractures in older patients, THA was associated with a lower risk of all-cause revision compared with unipolar and bipolar hemiarthroplasty among patients who were 60 to 79 years old and those who had an ASA classification of I or II. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

24 January 2024 in The Joint Commission Journal on Quality and Patient Safety
Verified
Journal Article
Closed access
HPHeather Prentice
Heather Prentice
JHJessica E. Harris
Jessica E. Harris
KSKenneth Sucher
Kenneth Sucher
BFBrian H. Fasig
Brian H. Fasig
RNRonald A. A. Navarro
Ronald A. A. Navarro
EPElizabeth W. Paxton
Elizabeth W. Paxton

30 November 2023 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
MKMonti Khatod
Monti Khatod
PCPriscilla H. Chan
Priscilla H. Chan
HPHeather Prentice
Heather Prentice
BFBrian H. Fasig
Brian H. Fasig
EPElizabeth W. Paxton
Elizabeth W. Paxton
MKMatthew P. Kelly
Matthew P. Kelly

17 October 2024 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
MKMonti Khatod
Monti Khatod
PCPriscilla H. Chan
Priscilla H. Chan
HPHeather Prentice
Heather Prentice
BFBrian H. Fasig
Brian H. Fasig
EPElizabeth W (Liz) Paxton
Elizabeth W (Liz) Paxton
MKMatthew P. Kelly
Matthew P. Kelly
Background: The increased availability of dual-mobility acetabular constructs (DMCs) provides surgeons with a newer option to increase the effective femoral head size in revision total hip arthroplasty (rTHA). We sought to evaluate risks of re-revision and prosthetic dislocation following rTHA involving a DMC compared with other articulations. Methods: A cohort study was conducted using data from a U.S. integrated health-care system’s Total Joint Replacement Registry. Adult patients who underwent primary THA and went on to undergo an aseptic rTHA in 2002 to 2022 were identified. Patients who received a DMC, a constrained liner, or a metal or ceramic unipolar femoral head on highly cross-linked polyethylene (XLPE) at the time of rTHA were the treatment groups. Subsequent aseptic re-revision and dislocation were the outcomes of interest. Multivariable Cox proportional-hazards regression was used to evaluate the risks of the outcomes, with adjustment for patient, operative, and surgeon confounders. Results: The analyzed rTHAs comprised 375 with a DMC, 268 with a constrained liner, 995 with a <36-mm head on XLPE, and 2,087 with a ≥36-mm head on XLPE. DMC utilization increased from 1.0% of rTHAs in 2011 to 21.6% in 2022. In adjusted analyses, a higher re-revision risk was observed for the constrained liner (hazard ratio [HR] = 2.43, 95% confidence interval [CI] = 1.29 to 4.59), <36 mm on XLPE (HR = 2.05, 95% CI = 1.13 to 3.75), and ≥36 mm on XLPE (HR = 2.03, 95% CI = 1.19 to 3.48) groups compared with the DMC group. A higher dislocation risk was observed in both XLPE groups (<36 mm: HR = 2.04, 95% CI = 1.33 to 3.14; ≥36 mm: HR = 2.46, 95% CI = 1.69 to 3.57) compared with the DMC group; a nonsignificant trend toward a higher dislocation rate in the group with a constrained liner than in the DMC group was also observed. Conclusions: In a large U.S.-based cohort, rTHAs using DMCs had the lowest re-revision risk and dislocation risk. Both outcomes were significantly lower than those using a unipolar femoral head on XLPE, re-revision risk was significantly lower than using a constrained liner, and dislocation risk trended toward a lower risk than using a constrained liner. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

28 March 2025 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
ZMZachary O. Mallon
Zachary O. Mallon
HPHeather Prentice
Heather Prentice
ASAdam M. Schlauch
Adam M. Schlauch
BFBrian H. Fasig
Brian H. Fasig
EPElizabeth W (Liz) Paxton
Elizabeth W (Liz) Paxton
KOKanu Okike
Kanu Okike
Background: While the Femoral Neck System (FNS) is increasingly utilized for the fixation of femoral neck fractures in elderly patients, studies comparing the device to the historical standard (that is, multiple cannulated screws) are lacking. The purpose of this study was to determine the risk of all-cause revision following fixation with the FNS device compared with multiple cannulated screws in patients ≥60 years of age with a femoral neck fracture. Methods: Patients ≥60 years of age who underwent fixation of a femoral neck fracture with the FNS or 3 cannulated screws (2017 to 2022) were identified using the Kaiser Permanente Hip Fracture Registry. Exclusion criteria were polytrauma, pathologic fracture, open fracture, additional surgeries at other sites during the same hospital stay, and prior procedures on the affected hip. The primary outcome measure was all-cause revision surgery, and the secondary outcome measures were mortality, emergency department visits, and readmissions. Multivariable Cox proportional hazards or logistic regression was performed, controlling for a wide range of potential confounders. Results: A total of 352 FNS and 1,686 cannulated-screw repairs were included. The overall incidence of revision at 2 years was 4.0% and 4.8% for the FNS and cannulated-screw constructs, respectively. Mortality at 2 years was 23.6% and 25.2%, respectively. In the adjusted analysis, no difference in all-cause revision risk was observed when comparing the FNS to cannulated screws (hazard ratio [HR] = 0.92, 95% confidence interval [CI] = 0.50 to 1.71; p = 0.79). A subgroup analysis of procedures performed by surgeons who used both devices also did not demonstrate a difference in revision rates (HR = 0.91; 95% CI = 0.39 to 2.17; p = 0.84). Conclusions: In this study of patients ≥60 years of age with a femoral neck fracture, the rates of all-cause revision and mortality were found to be similar between the FNS and multiple cannulated screws. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

21 April 2026 in Clinical Orthopaedics and Related Research
Verified
Journal Article
Closed access
SSSung Jun Son
Sung Jun Son
TSTanmaya D. Sambare
Tanmaya D. Sambare
HSHong Sun
Hong Sun
BFBrian H. Fasig
Brian H. Fasig
NRNithin C. Reddy
Nithin C. Reddy
HPHeather A. Prentice
Heather A. Prentice
Background: Benchmarking seeks to evaluate implant survivorship at certain follow-up time points against predetermined standards. The International Society of Arthroplasty Registries (ISAR) International Prosthesis Benchmarking Working Group (IPBWG) developed a predefined set of standards in which receiving a benchmark indicates that an implant has acceptable revision-free survivorship, whereas not receiving a benchmark suggests that the revision rate exceeded these established standards. Although benchmarking of TKA implant systems has been performed in select international countries, applications of benchmarks to TKA systems used in a US-based cohort are lacking. Questions/purposes: We sought to apply the ISAR IPBWG benchmarking standards to our US-based healthcare system’s total joint replacement registry and identify TKA implant systems meeting (1) early 2- and 5-year benchmarks, (2) midpoint 10-year benchmarks, and (3) late 15-year benchmarks. As a secondary aim, we sought to evaluate the consistency of these benchmarks when stratified by patient gender and age. Methods: Data from our US-based healthcare system’s Total Joint Replacement Registry were used to conduct a retrospective cohort study. The registry is well suited for benchmarking analyses because it captures all primary and revision TKAs performed within a closed, longitudinal healthcare system, enabling near-complete outcome tracking and comprehensive implant tracking through barcode-based documentation, with routinely audited administrative and clinical coding. Patient follow-up was 96%, 91%, 85%, and 80% at 2, 5, 10, and 15 years, respectively. Surgeons complete intraoperative registry forms via the electronic health record (EHR) for all TKAs, which are crosschecked against implant information—including manufacturer, implant name, and catalog number—recorded in the EHR via barcode scan and extracted into the registry. Patients are longitudinally followed for revision surgery until healthcare plan termination or death, and all identified revisions are manually validated through chart review. We identified all primary TKAs for osteoarthritis performed from January 1, 2001, through December 31, 2024. The final sample included 288,584 primary TKAs performed by 605 surgeons at 68 facilities. The cohort had a mean ± SD age of 68 ± 9 years, mean ± SD BMI of 31.2 ± 5.5 kg/m 2 , was predominantly women (61% [176,641 of 288,584]), and largely comprised patients with ASA class I to II (59% [171,306 of 288,584]). Each unique implant system, defined as the femoral and tibial component brand, fixation for each component, insert stability, and tibial insert mobility, was evaluated separately; systems with < 250 TKAs recorded into the registry were excluded. All-cause revision incidence during follow-up was evaluated using 1 – the Kaplan-Meier estimate and reported as cumulative percent revision (CPR) and 95% confidence interval (CI). Benchmark standards proposed by the IPBWG were used to evaluate the 2-, 5-, 10-, and 15-year time points; at each time point, at least 250 TKAs had to remain at risk to receive a benchmark. Implant systems received an early benchmark at 2 and 5 years after the primary TKA when the lower bound of the CPR 95% CI was less than or equal to the revision rate benchmark standards of 2% and 3%, respectively. Superiority and noninferiority relative to the benchmark standard were determined for 10-year midpoint and 15-year late benchmarks; the noninferiority margin was set at a 20% higher relative revision rate than the benchmark standard. For the 10-year time point, the system was considered superior when the upper bound of the 95% CI was less than or equal to 5%; when the upper bound of the 95% CI was less than or equal to 6% (20% above the 5% benchmark standard, or a 1% noninferiority margin), the system was considered noninferior; when it was above 6%, the system did not receive a 10-year benchmark. For the 15-year time point, systems with the upper bound of the 95% CI less than or equal to 6.5% were considered superior, and those in which the upper bound was less than or equal to 7.8% were considered noninferior; systems in which the 95% CI was above the noninferiority margin did not receive a benchmark. Results: Of the 45 TKA implant systems evaluated, 93% (42) received a benchmark at 2 years, representing 99% (284,929 of 288,584) of the TKAs included. The three implant systems not receiving a 2-year benchmark included the Smith & Nephew cemented, bicruciate-stabilized, fixed-bearing Journey ™ (n = 889; CPR 3.1 [95% CI 2.1 to 4.5]); the Smith & Nephew cemented, bicruciate-stabilized, fixed-bearing Journey II/Journey (n = 2200; CPR 2.8 [95% CI 2.1 to 3.6]); and the Zimmer Biomet cemented, ultracongruent or anterior-stabilized, fixed-bearing Natural Knee®/Natural Knee II (n = 566; CPR 3.9 [95% CI 2.6 to 5.9]). Of the 42 implant systems evaluated for 5-year benchmarks, 88% (37) received a benchmark, representing 96% (274,056 of 286,020) of the cohort evaluated for this time point. Five implants did not receive a 5-year benchmark: the DePuy cemented, posterior-stabilized, rotating PFC Sigma®/MBT (n = 7899; CPR 3.6 [95% CI 3.2 to 4.0]); the Smith & Nephew cemented, bicruciate-stabilized, fixed-bearing Journey (n = 889; CPR 5.4 [95% CI 4.1 to 7.1]); the Smith & Nephew cemented, bicruciate-stabilized, fixed-bearing Journey II/Journey (n = 2200; CPR 5.1 [95% CI 4.1 to 6.4]); the Zimmer Biomet cemented, cruciate-retaining, fixed-bearing Natural Knee II (n = 410; CPR 4.9 [95% CI 3.2 to 7.7]); and the Zimmer Biomet cemented, ultracongruent or anterior-stabilized, fixed-bearing Natural Knee/Natural Knee II (n = 566; CPR 5.9 [95% CI 4.2 to 8.2]). Of 25 implant systems considered for the 10-year benchmark, 52% (13) of systems received a superior benchmark, and 16% (4) of systems received a noninferior benchmark. Eight implant systems did not receive any 10-year benchmark. Implant systems receiving a superior benchmark were used in 91% (204,633 of 224,619) of the eligible TKAs, whereas implants that did not receive any 10-year benchmark were used in only 3% (6385 of 224,619) of the eligible TKAs. At the 15-year time point, 50% (6 of 12) of the implant systems evaluated received a superior benchmark, representing 89% (119,871 of 135,060) of the cohort evaluated at this time point. Forty-two percent (5) of the implant systems received a noninferior benchmark, and 8% (1) of the systems did not receive a benchmark at the 15-year time point. The same implant systems consistently failed to receive benchmarks at various time points in gender- and age-stratified analyses. Conclusion: Applying IPBWG benchmarking to a large US-based arthroplasty registry identified TKA implant systems with consistently inferior, adequate, or superior revision performance at mid- and long-term follow-up. These findings support prioritizing implant systems that meet benchmark standards for primary TKA and reevaluating routine use of implants that fail to achieve benchmarks when alternatives with reliable mid- and long-term performance are available. Future studies integrating benchmarking with risk-adjusted analyses are needed to clarify factors driving implant performance and to strengthen postmarket surveillance. Level of Evidence: Level III, therapeutic study.